Mitsubishi Tanabe Pharma America (MTPA) is a subsidiary of Mitsubishi Tanabe Pharma Corporation, a historic Japanese pharmaceutical company. Established in 2016 and based in Jersey City, New Jersey, MTPA focuses on discovering and developing treatments for serious diseases, including Multiple Sclerosis (MS), Diabetes Mellitus (DM), and Amyotrophic Lateral Sclerosis (ALS). The company is committed to improving patient health and adheres to high ethical standards.
MTPA engages in the research, development, and commercialization of pharmaceutical products. Notable products include Radicava, an intravenous treatment for ALS, and Exservan, an orally disintegrating tablet for ALS patients. The company serves healthcare providers, infusion centers, and patients across the United States, offering resources to support treatment and care. With a dedicated team of approximately 130 employees, MTPA continues to build on its parent company's legacy by addressing unmet medical needs in the U.S. market.
Mitsubishi Tanabe Pharma America (MTPA) is a subsidiary of Mitsubishi Tanabe Pharma Corporation, a historic Japanese pharmaceutical company. Established in 2016 and based in Jersey City, New Jersey, MTPA focuses on discovering and developing treatments for serious diseases, including Multiple Sclerosis (MS), Diabetes Mellitus (DM), and Amyotrophic Lateral Sclerosis (ALS). The company is committed to improving patient health and adheres to high ethical standards.
MTPA engages in the research, development, and commercialization of pharmaceutical products. Notable products include Radicava, an intravenous treatment for ALS, and Exservan, an orally disintegrating tablet for ALS patients. The company serves healthcare providers, infusion centers, and patients across the United States, offering resources to support treatment and care. With a dedicated team of approximately 130 employees, MTPA continues to build on its parent company's legacy by addressing unmet medical needs in the U.S. market.
